Introducing the latest medical devices from overseas manufacturers to Japan
First written in FY2016. 20 of 27 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Occlutech Holding; Switzerland; Structural heart disease treatment devices; Exclusive distribution rights in Japan; Through 31 January 2036 (automatic renewal every 5 years thereafter)」
The company disclosed a long-term exclusive distribution agreement in Japan with an overseas manufacturer for structural heart disease treatment devices, expanding the fields in which products manufactured by overseas companies are introduced into Japan to include structural heart disease. - FY2026-H1AdvancedAnnual report
「The launch of sales of Philips lead management devices in May 2025 also contributed.」
Regarding the domestic introduction of products manufactured by overseas companies, the company began selling Philips lead management devices in May 2025. - FY2025AdvancedAnnual report
「The company accelerated market penetration of the femoral venous hemostasis device launched in the previous fiscal year, growing the business to more than ¥2 billion within 1 year of launch. As of the end of the fiscal year, the device had been adopted by approximately 400 facilities, equivalent to half of all facilities nationwide performing ablation procedures, and was used in approximately 30% of atrial fibrillation cases.」
As part of its trading-company function of introducing products manufactured by overseas companies and others into Japan, the femoral venous hemostasis device expanded to more than ¥2 billion in sales and adoption by approximately 400 facilities within 1 year of launch. - FY2025-H1AdvancedAnnual report
「Market penetration of the femoral venous hemostasis device, positioned as a medium-term growth driver, progressed further, and revenue from the business increased 16.3% year on year.」
Market penetration of femoral venous hemostasis devices, including VASCADE MVP, progressed, and revenue from the related business increased 16.3% year on year. - FY2024-Q3AdvancedAnnual report
「The VASCADE MVP femoral venous hemostasis device announced in the third quarter was well received by medical professionals and got off to a strong start in sales.」
The company announced the new VASCADE MVP femoral venous hemostasis device, which got off to a strong start in sales. - FY2024-Q1AdvancedAnnual report
「On 28 June 2023, the company entered into an exclusive sales agency agreement in Japan with Hemonetics Japan LLC for a femoral venous hemostasis device.」
The company entered into an exclusive sales agency agreement in Japan for a femoral venous hemostasis device. The agreement runs from 28 June 2023 to 31 March 2027 and provides for one automatic renewal of 1 year thereafter. - FY2023-Q2AdvancedAnnual report
「In August 2022, the company entered into a 10-year exclusive distribution agreement with Wallaby Medical covering 11 endovascular neurovascular devices, substantially expanding its product lineup.」
The company entered into a 10-year exclusive distribution agreement in Japan with Wallaby Medical covering 11 endovascular neurovascular devices, expanding the domestic introduction of products manufactured by overseas companies into the neurovascular field. - FY2022Early termination of the exclusive distribution agreement and discussions following the supplier acquisitionAnnual report
「In February 2022, the company decided to terminate early, effective June 2022, the exclusive distribution agreement for drug-eluting coronary stents in the interventional field.」
While continuing to introduce products manufactured by overseas companies into Japan, the company decided to end the exclusive distribution agreement for Orsiro early, moving the end date forward from the originally scheduled end of March 2023 to the end of June 2022. It also stated that discussions were under way regarding continuation of the agreement following the acquisition of Baylis Medical. - FY2022-Q3Quantifies the revenue decline resulting from the end of salesAnnual report
「In addition, revenue from PI-related products declined significantly year on year because the end of sales of crossing catheters in December 2020 had a ¥264 million negative impact on revenue.」
The revenue decline resulting from the end of sales of crossing catheters in December 2020 was quantified at ¥264 million. - FY2022-Q1Reflects the end of sales of crossing cathetersAnnual report
「Sales of crossing catheters ended in December 2020.」
The end of sales in December 2020 of crossing catheters, one of the products manufactured by an overseas company that had been introduced in Japan, was specifically stated in the sales results. - FY2021Termination of agreement for a product scheduled for launchAnnual report
「The agreement was terminated on 31 May 2021 because delays in product development by Conavi Medical meant that commercialization was no longer foreseeable.」
The agreement for products including the 3D intracardiac echocardiography catheter system was terminated on 31 May 2021 due to delays in product development. This does not state that the company ended the domestic introduction of all products manufactured by overseas companies. - FY2021-Q3End of exclusive distribution agreement for coronary crossing cathetersAnnual report
「Contract product: Coronary crossing catheter; Contract terms: Exclusive distribution rights in Japan; Contract period: 1 January 2020 to 31 December 2020」
The exclusive distribution agreement in Japan for coronary crossing catheters with Teleflex Medical Europe ended on 31 December 2020. This does not state that the company ended the domestic introduction of all products manufactured by overseas companies. - FY2021-Q2AdvancedAnnual report
「In pacemaker-related products used to treat bradycardia, sales increased year on year as the ACCOLADE series of cardiac pacemakers performed steadily after the start of distribution in September 2019, supported by positive recognition of features including long battery life.」
Domestic distribution of the overseas-manufactured ACCOLADE series performed steadily after its launch in September 2019, contributing to higher sales year on year. - FY2020-Q3AdvancedAnnual report
「Exclusive distribution rights in Japan. Contract period: 1 January 2020 to 31 December 2020, with renewal by consultation each year.」
For the exclusive distribution agreement with Teleflex Medical Europe covering coronary crossing catheters, the company moved from interim transactions to a new contract beginning in January 2020 and entered into an agreement through the end of 2020. - FY2020-Q2AdvancedAnnual report
「For rhythm devices, under the exclusive distribution agreement signed in 2018, the planned change in supplier for CRM-related products from the former business partner to Boston Scientific Japan K.K. was completed in September 2019.」
For BSC’s CRM-related products, the company moved from advance sales of S-ICD to full-scale sales including other CRM products. It also entered into a sales support agreement covering September 2019 to August 2022. - FY2020-Q1AdvancedAnnual report
「Before the full-scale launch of Boston Scientific’s CRM-related products in September 2019, the company began sales in April 2019 of EMBLEM MRI S-ICD, a one-of-a-kind S-ICD product used to treat tachycardia.」
For Boston Scientific’s CRM products, the company began advance sales of S-ICD and is preparing for the full-scale launch in September 2019. The exclusive distribution agreement for Orsiro was also extended through the end of March 2023. - FY2019AdvancedAnnual report
「The company entered into an exclusive distribution agreement in Japan with Boston Scientific Japan K.K. for CRM (Cardiac Rhythm Management) products, securing a business foundation for long-term growth.」
The company entered into an exclusive distribution agreement in Japan for CRM-related products and prepared its operating structure for full-scale sales beginning in September 2019. It also began advance sales of the S-ICD system in April 2019. - FY2019-Q3AdvancedAnnual report
「During the third quarter of the fiscal year, the company entered into the following material business agreement. Contract product: stent graft for treating thoracic aortic disease. Contract terms: exclusive distribution rights in Japan. Contract period: 10 years from the date on which the reimbursement price for the product is determined, with renewal by consultation every 5 years thereafter.」
The company obtained exclusive distribution rights in Japan for Endospan’s stent graft for treating thoracic aortic disease for 10 years. In addition, it extended its exclusive distribution agreement for coronary crossing catheters with Teleflex Medical Europe through the end of June 2019. - FY2019-Q2AdvancedAnnual report
「The company entered into an agreement granting it exclusive distribution rights in Japan for Boston Scientific Corporation’s CRM-related products. The contract runs for 10 years from 1 September 2019, with automatic renewal every 2 years thereafter.」
The company entered into an exclusive distribution agreement in Japan for Boston Scientific’s CRM-related products. It is preparing for the launch in September 2019, and the contract has a scale involving a ¥3 billion upfront payment. - FY2019-Q1AdvancedAnnual report
「During the first quarter of the fiscal year, the company extended its contract with Teleflex Medical Europe because the contract period was due to expire.」
The company extended its contract with Teleflex Medical Europe, which acquired Vascular Solutions, continuing its exclusive distribution rights in Japan for the coronary crossing catheter. - FY2018AdvancedAnnual report
「Against this backdrop, the company began joint research and development with Endologix last September, building a partnership that goes beyond the conventional manufacturer-trading company relationship and taking its trading company functions to a new stage. In March of this year, it also began sales of Orsiro, a major drug-eluting coronary stent and the company’s first product in this category.」
The company began joint research and development with an overseas manufacturer, advancing collaboration beyond the conventional distribution agency relationship. It also began domestic sales of Orsiro. - FY2018-Q3AdvancedAnnual report
「In January of this year, the company obtained regulatory approval for Orsiro, a new drug-eluting coronary stent and a major device in the interventional field. It is preparing for a March launch and working to capture market share at an early stage.」
The company obtained regulatory approval for Orsiro and moved to preparations for a March 2018 launch. - FY2018-Q2AdvancedAnnual report
「Contract product: stent graft for treating thoracic aortic disease. Contract terms: exclusive distribution rights in Japan. Contract period: 15 years from the date on which the reimbursement price for the product is determined.」
The company obtained exclusive distribution rights in Japan for Endologix’s stent graft for treating thoracic aortic disease for 15 years from the date on which the reimbursement price was determined. It also entered into an exclusive distribution agency agreement in Japan with TERUMO CORPORATION for products manufactured by Bolton Medical. - FY2018-Q1RestatedAnnual report
「In the interventional field, the company is preparing for the launch in the fourth quarter of Orsiro, a drug-eluting coronary stent and a major treatment device for coronary artery disease.」
Preparations for the fourth-quarter launch of Orsiro are continuing, but the filing does not state any new milestone beyond the plan presented in the previous filing. - FY2017AdvancedAnnual report
「In February of this year, the company entered into an exclusive distribution agreement for Orsiro, a drug-eluting coronary stent manufactured by BIOTRONIK and a major treatment device for coronary artery disease, and is preparing for its launch in the fourth quarter of the next fiscal year.」
The company entered into an exclusive distribution agreement with overseas manufacturer BIOTRONIK and moved to preparations for a domestic launch in the fourth quarter of the next fiscal year. - FY2017-Q3AdvancedAnnual report
「During the third quarter of the fiscal year, following the expiration of the contract period with Vascular Solutions, the company entered into a new contract as follows. Contract product: coronary crossing catheter. Contract terms: exclusive distribution rights in Japan. Contract period: 1 January 2017 to 31 December 2017.」
Following the expiration of the contract period with the overseas company, the company entered into a new agreement for exclusive distribution rights in Japan for the coronary crossing catheter. - FY2016First statedAnnual report
「The company will continue to leverage the network it has built to identify highly innovative medical devices from overseas manufacturers and work to introduce them to Japan.」
A strategy to introduce products from overseas manufacturers without an established presence in Japan to domestic clinical practice, drawing on experience in regulatory approvals and a nationwide sales network.